Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes

Figure 1

Low BCAR3 expression predicts poor prognosis in human breast cancer. (a) and (b) Kaplan-Meier survival curves generated by the GOBO gene expression–based outcome tool showing the status of disease-free survival (DFS) of a compiled cohort of breast cancer patients who underwent various treatment plans (a) and a compiled cohort of patients who received no systematic treatment (b). Patients were separated by the median signal intensity from an Affymetrix probe targeting BCAR3 (204032_at) in microarray analysis. Survival data of the high-expression group are shown by the red curve, and those of the low-expression group are shown by the gray curve. (c) and (d) Kaplan-Meier survival curves showing the status of distant metastasis-free survival (DMFS) of a compiled cohort of breast cancer patients who underwent various treatments (c) and a compiled cohort of patients who received no systematic treatment (d). Patients were separated by median signal intensity of 204032_at. (e) and (f) Kaplan-Meier survival curves showing status of relapse-free survival (RFS) of a compiled cohort of breast cancer patients who underwent various treatment plans (e) and a compiled cohort of patients who received no systematic treatment (f). Patients were separated by median signal intensity (e) or into five groups (f). (g) Dot plot of reading of the probe targeting BCAR3 extracted from the National Center for Biotechnology Information Gene Expression Omnibus dataset GDS807, which includes microarray readings of gene expression in microdissected primary tumors from patients who subsequently received tamoxifen treatment for 5 years. (h) Percentage loss of heterozygosity at BCAR3 alleles in breast tumors with increasing N stage.

Back to article page